DU80 Stock Overview
A molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.95 |
| 52 Week High | AU$4.78 |
| 52 Week Low | AU$1.54 |
| Beta | 0.42 |
| 1 Month Change | -9.72% |
| 3 Month Change | 21.12% |
| 1 Year Change | -57.84% |
| 3 Year Change | -86.73% |
| 5 Year Change | n/a |
| Change since IPO | -90.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| DU80 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -8.0% | -0.2% | -0.3% |
| 1Y | -57.8% | -12.2% | 4.5% |
Return vs Industry: DU80 underperformed the German Life Sciences industry which returned -12.2% over the past year.
Return vs Market: DU80 underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| DU80 volatility | |
|---|---|
| DU80 Average Weekly Movement | 15.5% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DU80's share price has been volatile over the past 3 months.
Volatility Over Time: DU80's weekly volatility has increased from 10% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 60 | Simon Morriss | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| DU80 fundamental statistics | |
|---|---|
| Market cap | €9.74m |
| Earnings (TTM) | -€7.81m |
| Revenue (TTM) | €6.29m |
1.5x
P/S Ratio-1.2x
P/E RatioIs DU80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DU80 income statement (TTM) | |
|---|---|
| Revenue | AU$10.24m |
| Cost of Revenue | AU$3.94m |
| Gross Profit | AU$6.30m |
| Other Expenses | AU$19.01m |
| Earnings | -AU$12.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 61.50% |
| Net Profit Margin | -124.08% |
| Debt/Equity Ratio | 0% |
How did DU80 perform over the long term?
See historical performance and comparison